1) Ibrutinib licence. European Commission.
2) Garcia-Sanz R, Ocio EM. Novel treatment regimens for Waldenström's
macroglobulinemia. Expert Rev Hematol. 2010;3:339-50.
3) European Medicines Agency. Committee for Medicinal Products for Human Use: Summary of
opinion. Disponible
en: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/003791/WC500170191.pdf
. Ultima consulta en julio de 2015.
4) American Cancer Society. Detailed guide: Waldenström macroglobulinemia. Disponible
en: http://www.cancer.org/acs/groups/cid/documents/webcontent/003148-pdf.pdf Ul
tima consulta en julio de 2015.
5) Leukemia and Lymphoma Society. Waldenström macroglobulinemia facts. Disponible
en:http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/lymphoma/pdf/waldenstrommacroglobulinemia.pdf
. Ultima consulta en julio de 2015.
6) Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol. 2007;138:700-20.
7) Buske C, Leblond V, Dimopoulos M, et al. Waldenström's macroglobulinaemia: ESMO
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 2013;24(Suppl. 6):vi155-vi159.
8) Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant
cells expressing the L265P mutation in Waldenström's macroglobulinemia, and effect on
tumor cells with BTK-inhibitor PCI-32765 in combination with MYD88 pathway
inhibitors. J Clin Oncol. 2012;30(Suppl.):abstract 8106.
9) O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly
patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an
open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48-58.
10) Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's
macroglobulinemia. N Engl J Med. 2015;372:1430-40.
11) European Medicines Agency. How is the medicine expected to
work? http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/
0[6]/human_orphan_001058.jsp&mid=WC0b01ac058001d12b
[http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/06/human_orphan_001058.jsp&mid=WC0b01ac058001d12b ]
. Ultima consulta en julio de 2015.
Consultas a medios:
Natalie Buhl
Móvil: +353(0)85-744-6696
E-mail: nbuhl@its.jnj.com
Relaciones para inversores:
Lesley Fishman
Tel: +1-732-524-3922
Louise Mehrotra
Tel: +1-732-524-6491
PHEM/IBR/0615/0008
Julio de 2015
(Logo: http://photos.prnewswire.com/prnh/20140324/NY88746LOGO )
Photo:
http://photos.prnewswire.com/prnh/20140324/NY88746LOGO
Video:
http://www.multivu.com/players/uk/7571151-janssen-waldenstrom-macroglobulinemia
